What do systematic reviews say?

NB‐UVB vs UVA1

• Phototherapy for atopic eczema 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 46 participants
  Very low

UVA1 vs PUVA

The review found no eligible studies for this question.

• Phototherapy for atopic eczema 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NB‐UVB vs PUVA

The review found no eligible studies for this question.

• Phototherapy for atopic eczema 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NB‐UVB vs placebo

The review found no eligible studies for this question.

• Phototherapy for atopic eczema 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Minoxidil vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Very low

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found